Cumulative Irritation Test

• Drug: AN2690
  
  AN2690 Solution, 2.5%, Daily for up to 21 days
• Drug: AN2690
  
  AN2690 Solution, 7.5%, Daily for up to 21 days
• Drug: AN2690
  
  AN2690 Solution, 5.0%, Daily for up to 21 days
• Other: AN2690 Solution, Vehicle
  
  AN2690 Solution, Vehicle, Daily for up to 21 days
• Other: Sodium Lauryl Sulfate, 0.5%
  
  Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days

• Experimental: A
  
  AN2690 Solution, 2.5%
  Intervention: Drug: AN2690
• Experimental: B
  
  AN2690 Solution, 7.5%
  Intervention: Drug: AN2690
• Experimental: C
  
  AN2690 Solution, 5.0%
  Intervention: Drug: AN2690
• Active Comparator: D
  
  AN2690 Solution, Vehicle
  Intervention: Other: AN2690 Solution, Vehicle
• Active Comparator: E
  
  Sodium Lauryl Sulfate, 0.5%
  Intervention: Other: Sodium Lauryl Sulfate, 0.5%

Inclusion Criteria:

• Healthy, volunteers of either sex, at least 18 years of age or older
• Females of childbearing potential submitted to a urine pregnancy test and had negative results at Day 1 and at the final visit and also was using an effective method of birth control (e.g. abstinence, implants, injectables, oral contraceptives, intrauterine contraceptive devices or double barrier) or agreed to use an effective method of birth control prior to becoming sexual active
• Subjects were of any skin type or race providing their degree of pigmentation did not interfere with making readings of skin reactions
• Subjects were willing to follow the study procedures and complete the study
• Written informed consent was obtained

Exclusion Criteria:

• Subject with any skin disease that would have in any way confounded interpretation of the study results. Atopic dermatitis/eczema, psoriasis or chronic asthma were excluded
• Subject was pregnant or nursing
• Subject had a history of sensitivity to any component of any of the formulations
• Use of chronic medications (such as antihistamines, corticosteroids, analgesics and anti-inflammatories) for one week before and during the study